Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?
Table 2
Univariable Cox proportional hazard analysis for virologic breakthrough (HBV DNA ).
Parameter
Virologic breakthrough
HR (95% CI)
value
Treatment
Combination group
1 (reference)
Single group
2.16 (0.22–21.31)
0.51
Age (per year)
0.97 (0.89–1.05)
0.45
Male
2.04 (0.24–17.29)
0.52
HBeAg
Negative
1 (reference)
Positive
3.93 (0.46–33.67)
0.21
Previous history of HCC
Absent
1 (reference)
Present
0.75 (0.09–6.43)
0.79
Underlying LC
Absent
1 (reference)
Present
1.11 (0.22–5.48)
0.90
AST (per 1 IU/L)
1.02 (0.97–1.07)
0.50
ALT (per 1 IU/L)
1.004 (0.96–1.05)
0.87
Total bilirubin (per 1 mg/dL)
0.38 (0.04–3.99)
0.42
Albumin (per 1 g/dL)
0.93 (0.11–8.20)
0.95
rtA181 mutation
Absent
1 (reference)
Present
0.38 (0.04–3.29)
0.38
rtN236 mutation
Absent
1 (reference)
Present
0.51 (0.004–4.34)
0.61
Minor virologic breakthrough
Absent
1 (reference)
Present
0.51 (0.02–12.22)
0.68
Time-varying Cox was applied for analysis. Virologic breakthrough was defined as HBV DNA . Minor virologic breakthrough was defined as HBV DNA . Univariable factors were analyzed with Firth method. ALT: alanine aminotransferase; AST: aspartate aminotransferase; CI: confidence interval; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HR: hazard ratio; LC: liver cirrhosis.
